190results about "Viruses/bacteriophages" patented technology

The application discloses a kind of multi-modal biological aerosol simulation materials based on high stability fluorescent protein label and construction method thereof, belong to biological aerosol simulation technical field.The simulation material is made of the microorganism expressing StayGold fluorescent protein by genetic engineering modification, and is compounded with the hydrophobic silicon dioxide particles of specific particle size.The core of the present application is: first use the StayGold protein with excellent light stability as biomarker, overcome the defect that traditional fluorescent protein is easily quenched in simulation environment;Innovatively design the "microorganism-dust" composite particle structure, by optimizing the concentration of bacterial suspension, particle ratio and adding isopropyl alcohol additive, generate aerosol with particle size distribution of 1-10 μm by atomization technology, highly reproduce the physical and chemical state of biological aerosol in real environment.The simulation material maintains high survival rate and fluorescent signal stability in wide temperature range and wide humidity range.

This invention discloses a virulent strain of type I canine adenovirus and its application in constructing animal infection models, belonging to the field of biotechnology. The virulent strain of type I canine adenovirus is named canine adenovirus type 1 strain 0601, with accession number CCTCC NO: V202604. The virus titer reaches 10. 7.5 TCID 50 / mL. This virus can be used to construct an animal model of canine adenovirus type I infection, which exhibits typical clinical symptoms, such as hepatic hemorrhage, hepatocellular necrosis, and venous and sinusoidal congestion. The constructed animal model can be used for future canine adenovirus vaccine development, immune protection assessment, and efficacy evaluation of preventive and therapeutic drugs, providing excellent biological materials and theoretical basis for further control of canine adenovirus type I.

This specification provides a mutant adeno-associated virus serotype 9 (AAV9) capsid protein and recombinant AAV9 particles containing the mutant AAV9 capsid protein. Further provided are a pharmaceutical composition comprising recombinant AAV9 particles, a polynucleotide encoding the mutant AAV9 capsid protein, a vector and host cells containing the polynucleotide, a population of host cells transduced by the recombinant AAV9 particles, and various methods for using the recombinant AAV9 particles.

We provide vaccines against SARS-CoV-2 infection and related diseases. [Solution] A recombinant modified vaccinia virus ankara (MVA) is provided, comprising a nucleic acid sequence encoding the amino acid sequence of a full-length spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the amino acid sequence of the SARS-CoV-2 S full-length protein includes modifications that can stabilize the S protein in the pre-fusion three-dimensional structure.

The application discloses a recombinant oncolytic virus targeting CD317 gene and application thereof in anti-tumor, and belongs to the technical field of tumor treatment. The recombinant oncolytic virus comprises a CD317 inhibitor and an oncolytic virus, and is formed by integrating the CD317 inhibitor into the oncolytic virus genome. The CD317 inhibitor is a substance capable of inhibiting CD317 gene expression or targeting degradation of CD317 protein function, and is selected from shRNA or siRNA targeting CD317. The application develops the oncolytic virus targeting knockdown of CD317 expression, inhibits tumor cell proliferation by reducing CD317 expression of tumor cells, reduces PD-L1 expression so as to break the immune escape mechanism, simultaneously enhances the killing sensitivity of tumor cells to CD8+ T cells, forms a synergistic effect with the oncolysis of the oncolytic virus, and the recombinant oncolytic virus has stronger in-vivo anti-tumor activity, thereby providing a new potential scheme for CD317-driven tumor treatment.

The present disclosure provides methods and compositions for targeting lipid bilayer particles, such as secreted extracellular vesicles, and cargo entities contained therein, to recipient cells.

This invention discloses a virulent strain of type II canine adenovirus, an inactivated vaccine, and their applications, belonging to the field of biotechnology. The virulent strain of type II canine adenovirus is named canine adenovirus type 2 Aa05 strain, with accession number CCTCC NO: V202605. The virus titer can reach 10. 6.0 TCID 50 / mL. This invention utilizes this strain to construct an animal model of canine adenovirus type II infection. This animal model exhibits typical clinical symptoms and can be used for future canine adenovirus vaccine development, immune protection assessment, and efficacy evaluation of preventive and therapeutic drugs. This invention also utilizes this strain to develop an inactivated vaccine with extremely high safety and immunogenicity. It can induce the body to produce high levels of specific neutralizing antibodies, which can protect immunized animals against infection with virulent CAV-2 strains and also against infection with highly pathogenic CAV-1 strains, demonstrating excellent cross-protection.

Providing recombinant AD35 vectors and related gene therapy improvements. [Solution] This disclosure provides, among other things, a helper-dependent adenovirus serotype 35 (Ad35) vector. In various embodiments, the helper-dependent Ad35 vector can be used to deliver a therapeutic payload to a target that needs it. Examples of payloads may encode replacement proteins, antibodies, CARs, TCRs, small RNAs, and genome editing systems. In certain embodiments, the helper-dependent Ad35 vector is manipulated so that the payload is incorporated into the host cell genome. This disclosure further includes gene therapy methods comprising administering the helper-dependent Ad35 vector to a target that needs it.

In one aspect, the disclosure relates to pneumococcal vaccines comprising a semisynthetic saponin adjuvant VSA-1. In one aspect, the disclosed vaccines elicit an immune response in a subject that is measurably higher than the response in an otherwise identical subject who receives a vaccine without the semisynthetic saponin adjuvant. In another aspect, the disclosed vaccines are useful across age groups and immunization can be achieved with fewer injections than for standard pneumococcal vaccines. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The present disclosure relates to a low glycosylated influenza hemagglutinin (HA) protein and a vaccine designed to express the HA protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated HA protein, which provides a broader protection across different influenza strains or lineages.

A method of treating cancer in a subject that includes administering in situ to the cancer of the subject a therapeutically effective amount of a plant virus or plant virus-like particle in combination with administration of an immune checkpoint therapy to the subject.

The application discloses a method for treating hydrogen sulfide in oil wells, which comprises the following steps: (1) screening of test oil reservoir; (2) preparation of specific virulent SRB phage stock solution; (3) enrichment of specific virulent SRB phage; (4) determination of optimal titer of specific virulent SRB phage solution; (5) selection of phage fusion bactericide; (6) determination of optimal intervention point of bactericide; (7) field test and effect evaluation. The application has the following advantages: (1) wide adaptability, simple method and good operability; (2) strong pertinence; (3) phage bactericidal action can prevent the generation of bacterial drug resistance and can prolong the use time of bactericide; (4) the cost is reduced by more than 50% compared with the prior art; meanwhile, the damage of bactericide toxicity to the formation is reduced, and the method is economic and environment-friendly.

The application provides an AAV9 capsid protein variant and use thereof. Research finds that the AAV9 capsid protein is modified, and the modified amino acid sequence is shown in SEQ ID NO: 1, which can significantly escape neutralizing antibodies, and has significant positive significance for gene therapy.

This invention belongs to the field of microbial technology and discloses a strain of *Citrobacter freundii* bacteriophage PRF337, its bacteriophage composition, and its applications. The *Citrobacter freundii* bacteriophage PRF337 was deposited on May 26, 2025, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 46489. The bacteriophage PRF337 exhibits broad-spectrum bactericidal activity against *Citrobacter freundii*, capable of lysing *Citrobacter freundii* strains containing different virulence genes and from different sources. It also possesses certain temperature and pH stability and can be used as an active ingredient in pharmaceutical preparations, environmental disinfectants, and water purifiers. It can effectively control *Citrobacter freundii* infection in aquatic animals such as fish and shrimp in aquaculture environments and can also be used for the purification of pathogens in aquatic environments. It is safe to use and effectively avoids the problems of antibiotic residues and pathogen resistance caused by antibiotic use.

A lentivirus, comprising a BaEV envelope glycoprotein. The extracellular region of the BaEV envelope glycoprotein comprises at least one of the following sequences: a spacer sequence and a recognition sequence. The spacer sequence comprises a spacer unit, and the recognition sequence comprises BaEVSecSig-recognition protein-BaEVTM, wherein BaEVSecSig is a BaEV signal peptide, and BaEVTM is a BaEV transmembrane domain.

The application discloses a D type influenza virus isolate D / HY11 and application thereof in a mink infection model, and belongs to the field of biological medicines. The application takes the D type influenza virus isolate D / HY11 of an IDV northeast isolate as a research object, establishes a mink transmission model, evaluates the transmission dynamics characteristics of the strain among minks, identifies amino acid mutations possibly related to host adaptability through whole genome sequencing, analyzes the amino acid substitution on receptor affinity based on computer simulation of protein conformation and receptor molecule docking, explores the host adaptation evolution law of the virus in the transmission process, and provides an important scientific basis for early warning and prevention and control of a public health crisis possibly caused by the IDV.

The present invention relates to a polynucleotide comprising two inverted terminal repeats (ITRs), an hGRK1 promoter, an SV40 late intron, a transgene encoding an RPGR polypeptide, and an SV40 late polyA.

The application relates to the field of biological medicine, and discloses application of proline-rich protein 33 in preparation of a drug for cardiomyopathy related to cardiac hypertrophy. The application identifies a proline-rich protein 33 highly enriched in myocardial cells. Prr33 Gene deletion can aggravate myocardial cell hypertrophy and ventricular dysfunction, and its overexpression can inhibit cardiac hypertrophy. PRR33 protects the myocardium from pathological hypertrophy by stabilizing the LDB3-MYOZ2-calcineurin complex and inhibiting NFAT activation. These findings reveal a new regulatory level in the sarcomere signaling and highlight that PRR33 is expected to become a therapeutic target for preventing cardiomyopathy related to cardiac hypertrophy.

This invention relates to the field of biomedical technology, and in particular to an expression cassette, recombinant vector, and their applications for preparing attenuated influenza vaccines. This invention is the first to introduce the DD protein domain into the NS protein of influenza virus (A / PR8 / H1N1), constructing a conditionally replication-deficient virus (denoted as DDN-NS H1N1). The constructed virus exhibits limited replication in the absence of Shield-1, but recovers its replication ability in the presence of Shield-1, achieving external chemical control over viral replication. This results in a virus that combines high safety and strong immunogenicity, providing a new strategy for influenza vaccine development.

The application provides a porcine epidemic diarrhea virus mutant strain and application thereof. The application obtains a porcine epidemic diarrhea virus mutant strain GX2506 from porcine intestinal tissue, and the strain is purified through passage, and the microorganism preservation number of the strain is CGMCC No. 47089. The isolated strain can stably proliferate on a passage cell, and typical cytopathic effect is generated. The porcine epidemic diarrhea virus mutant isolated strain has excellent immunogenicity; a vaccine prepared by using the isolated strain can induce piglets to generate high-level neutralizing antibodies; meanwhile, an ELISA kit prepared by using the isolated strain can better detect porcine epidemic diarrhea virus antibodies in serum.

The application discloses a method for controlling antibiotic-resistant biofilm by using bacteriophages and deinococcus radiodurans, and belongs to the field of environmental biological technology and water treatment. The method adds lytic bacteriophages and deinococcus radiodurans as a composite microbial agent into an environmental water body where antibiotic-resistant biofilm is located, targets and lysates antibiotic-resistant bacteria in the antibiotic-resistant biofilm, and degrades accumulated and released intracellular antibiotic-resistant genes. The application can be used for biological control of antibiotic-resistant biofilm in water distribution and supply pipe networks, and avoids by-products caused by excessive chlorine disinfection.

This invention belongs to the field of biomedical technology, specifically relating to a method for constructing a highly cell-adaptive PEDV GIIc recombinant chimeric virus. Specifically, this invention, based on the PEDV viral S protein determining PEDV's cell adaptability, innovatively elucidates that S2 is the key subunit determining its cell adaptability. On this basis, this invention proposes a scheme that can increase viral titer and thus reduce vaccine production costs when preparing candidate vaccine strains of circulating PEDV strains (especially GIIc). This involves retaining the S2 subunit of the highly cell-adaptive strain and replacing the S1 subunit of the highly cell-adaptive strain with the S1 subunit of the circulating strain, or replacing the S2 subunit of the circulating strain with the S2 subunit of the highly cell-adaptive strain. This scheme can both preserve the immunogenicity of the circulating strain and improve the efficiency of high-titer vaccine production.

In one aspect, nerve ablation methods in the treatment of neurological diseases and disorders utilize AAV capsids which are taken up by peripheral nerves after local injection in the periphery. Compositions include vectors with genetic material encoding enzymes that induce apoptosis under a neuron-specific promoter.

The present disclosure provides a peptide-major histocompatibility complex (pMHC) polypeptide comprising a peptide epitope and class I MHC polypeptides. The present disclosure provides fusion molecules comprising a pMHC polypeptide and a heterologous fusion partner. The present disclosure provides single-chain T-cell modulatory polypeptides that comprise a pMHC polypeptide, one or more immunomodulatory polypeptide, and an immunoglobulin (Ig) Fc or a non-Ig scaffold. A TMP is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.

The application belongs to the technical field of bioengineering, and particularly relates to a bacteriophage PE-2 of Escherichia coli with high blood entry efficiency and fermentation efficiency and application. The bacteriophage involved in the application has a preservation number of CCTCC NO: M20252973, and can specifically lyse pathogenic Escherichia coli O2 serotype and has high blood entry efficiency. The bacteriophage can enter blood circulation through oral administration, and can be widely distributed to the spleen, liver, heart and other tissues through blood circulation. The bacteriophage can be prepared in pilot production to obtain a very high titer, and the titer reaches 1.6x10 12 PFU / mL. Compared with the production of antibiotics, the production cost of the bacteriophage is low, and the bacteriophage provides a source and a reference example for industrial production of high-titer bacteriophage.

The present invention provides an apparatus, method, and program for extracting multiple images of the same microorganism from multiple captured images. [Solution] In the system 10, the discrimination device 60 includes an acquisition unit that receives multiple images of the flow channel 24 through which microorganisms in the flow channel device 20 flow, and an extraction unit that extracts multiple images of the same individual microorganism from the multiple images. The flow channel through which microorganisms flow may have a vortex generator that generates vortices in the imaging range 26 that captures multiple images within the flow channel. The acquisition unit receives multiple images of the flow channel through which microorganisms flow, taken at different timings. The acquisition unit also receives multiple images taken from two or more different directions.

This invention discloses an attenuated chikungunya virus expressing a nanoluciferase gene, the nucleotide sequence of which is shown in SEQ ID NO:1. It is constructed by attenuating the virulence of the chikungunya virus LR2006-OPY1 strain by deleting 61 amino acids from positions 323 to 383 of the nsP3 protein and inserting a nanoluciferase gene after position 490 of the nsP3 protein. This virus model maintains similar growth characteristics to the wild-type virus but with significantly improved safety. Viral replication can be monitored in real time by detecting luciferase activity, making it suitable for drug screening at both cellular and animal levels. This provides an efficient and safe technical platform for the development of antiviral drugs against chikungunya virus.

The application provides a method for improving lentivirus infection efficiency of cells. The method comprises the following steps: S1, culturing target cells by using a first culture medium to obtain a first culture solution; S2, adding lentivirus, a second culture medium containing 0.5-1.5 vol% FBS or 800-1200 U / mL IL-2 into the first culture solution, and centrifuging at 33-35 DEG C, 600-1000 g for 30-120 min to obtain a second culture solution; S3, adding a third culture medium containing 25-35 vol% FBS or 1800-2200 U / mL IL-2 into the second culture solution and continuing to culture to obtain lentivirus infected cells. The method provided by the application uses the first culture medium to culture the target cells in advance, and then uses the constant temperature centrifugation method and the second culture medium to infect the lentivirus, and uses the third culture medium to continue to culture the lentivirus infected target cells after the lentivirus infection, so that the positive rate of the lentivirus infected target cells and the survival rate of the target cells after the infection can be improved.